Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Decreased T-cell responses to influenza vaccination in patients with heart failure.

Vardeny O, Moran JJ, Sweitzer NK, Johnson MR, Hayney MS.

Pharmacotherapy. 2010 Jan;30(1):10-6. doi: 10.1592/phco.30.1.10.

2.

Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.

Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.

Pediatrics. 2006 Sep;118(3):e579-85.

PMID:
16950949
3.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
4.

Lack of persistence of influenza vaccine antibody titers in patients with heart failure.

Albrecht CM, Sweitzer NK, Johnson MR, Vardeny O.

J Card Fail. 2014 Feb;20(2):105-9. doi: 10.1016/j.cardfail.2013.12.008. Epub 2013 Dec 19.

5.

Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study.

Van Ermen A, Hermanson MP, Moran JM, Sweitzer NK, Johnson MR, Vardeny O.

Eur J Heart Fail. 2013 May;15(5):560-4. doi: 10.1093/eurjhf/hfs207. Epub 2013 Jan 4.

6.

Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.

PLoS One. 2013 Aug 16;8(8):e70866. doi: 10.1371/journal.pone.0070866. eCollection 2013.

7.

Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease.

Hagihara Y, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, Kamata N, Sogawa M, Shiba M, Tanigawa T, Tominaga K, Watanabe T, Fujiwara Y, Hirota Y, Arakawa T.

J Crohns Colitis. 2014 Mar;8(3):223-33. doi: 10.1016/j.crohns.2013.08.008. Epub 2013 Sep 5.

PMID:
24011513
8.

A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings.

Madan RP, Tan M, Fernandez-Sesma A, Moran TM, Emre S, Campbell A, Herold BC.

Clin Infect Dis. 2008 Mar 1;46(5):712-8. doi: 10.1086/527391.

9.

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.

Vaccine. 2013 May 1;31(19):2358-65. doi: 10.1016/j.vaccine.2013.03.008. Epub 2013 Mar 13.

PMID:
23499604
10.
11.

T cell responses are better correlates of vaccine protection in the elderly.

McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC.

J Immunol. 2006 May 15;176(10):6333-9.

12.

Lung transplant patients' T cell responses to influenza vaccine viruses between seasons.

Hayney MS, Moran J, Wiegert NA, Burlingham WJ.

Vaccine. 2008 May 19;26(21):2596-600. doi: 10.1016/j.vaccine.2008.03.012. Epub 2008 Mar 31.

PMID:
18420314
13.

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.

Frenck RW Jr, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB Jr, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.

Vaccine. 2011 Aug 5;29(34):5666-74. doi: 10.1016/j.vaccine.2011.06.010. Epub 2011 Jun 23.

14.

Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.

Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, Wu Y, Xie ML, Cheong A, Leo YS, Chow VT.

Int J Infect Dis. 2012 Aug;16(8):e621-7. doi: 10.1016/j.ijid.2012.04.010. Epub 2012 Jun 15.

15.

Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine.

Zeman AM, Holmes TH, Stamatis S, Tu W, He XS, Bouvier N, Kemble G, Greenberg HB, Lewis DB, Arvin AM, Dekker CL.

Pediatr Infect Dis J. 2007 Feb;26(2):107-15.

PMID:
17259871
16.

Decreased immune responses to influenza vaccination in patients with heart failure.

Vardeny O, Sweitzer NK, Detry MA, Moran JM, Johnson MR, Hayney MS.

J Card Fail. 2009 May;15(4):368-73. doi: 10.1016/j.cardfail.2008.11.009. Epub 2008 Dec 18.

17.

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.

Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

BMC Infect Dis. 2013 Jul 24;13:343. doi: 10.1186/1471-2334-13-343.

18.

Vaccination against influenza in patients with systemic sclerosis.

Litinsky I, Balbir A, Zisman D, Mandelboim M, Mendelson E, Feld J, Braun Y, Anouk M, Kaufman I, Paran D, Caspi D, Elkayam O.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S7-11. Epub 2012 May 29.

PMID:
22409886
19.

Antibody responses to trivalent influenza vaccine in Iranian adults infected with human immunodeficiency virus.

Rasoolinejad M, Jafari S, Montazeri M, Mohseni M, Foroughi M, Moradmand Badie B, Saatian M, Marashi SM, Mokhtari Azad T.

Acta Med Iran. 2013 Apr 6;51(3):148-52.

20.

Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects.

Agrati C, Castilletti C, Cimini E, Lapa D, Quartu S, Caglioti C, Lanini S, Cattoli G, Martini F, Ippolito G, Capobianchi MR.

PLoS One. 2014 Aug 27;9(8):e105651. doi: 10.1371/journal.pone.0105651. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk